In the last trading session, 71.13 million Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares changed hands as the company’s beta touched 2.07. With the company’s per share price at $0.43 changed hands at $0.05 or 14.16% during last session, the market valuation stood at $80.01M. TNXP’s last price was a discount, traded about -2802.33% off its 52-week high of $12.48. The share price had its 52-week low at $0.12, which suggests the last value was 72.09% up since then. When we look at Tonix Pharmaceuticals Holding Corp’s average trading volume, we note the 10-day average is 143.33 million shares, with the 3-month average coming to 126.96 million.
Analysts gave the Tonix Pharmaceuticals Holding Corp (TNXP) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended TNXP as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Tonix Pharmaceuticals Holding Corp’s EPS for the current quarter is expected to be -7.68.
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) trade information
Instantly TNXP was in green as seen at the end of in last trading. With action 11.75%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 29.81%, with the 5-day performance at 11.75% in the green. However, in the 30-day time frame, Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) is 18.88% up. Looking at the short shares, we see there were 7.67 million shares sold at short interest cover period of 0.35 days.
Tonix Pharmaceuticals Holding Corp (TNXP) estimates and forecasts
Data shows that the Tonix Pharmaceuticals Holding Corp share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -13.71% over the past 6 months, a 91.94% in annual growth rate that is considerably higher than the industry average of 17.30%. Year-over-year growth is forecast to reach 64.78% up from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 3.2M. 1 analysts are of the opinion that Tonix Pharmaceuticals Holding Corp’s revenue for the current quarter will be 4.2M. The company’s revenue for the corresponding quarters a year ago was 3.78M and 2.48M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -15.32%. The estimates for the next quarter sales put growth at 69.22%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 79.31%. The 2025 estimates are for Tonix Pharmaceuticals Holding Corp earnings to increase by 95.88%.
TNXP Dividends
Tonix Pharmaceuticals Holding Corp is expected to release its next quarterly earnings report in March.
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.17% of Tonix Pharmaceuticals Holding Corp shares while 0.23% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 0.23%.
Among Mutual Funds, the top two as of Oct 31, 2024 were Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund . With 113.13 shares estimated at $48432.0 under it, the former controlled 0.06% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.00% of the shares, roughly 7.3 shares worth around $3125.0.
